Rui Avelar, M.D.

Rui Avelar, M.D.

Chief Medical Officer and Head of Research and DevelopmentatEvolus· In proxies 2022–2025

Pay in FY2025-41% from the year before · Evolus stock -39.8% the same year

Rui Avelar, M.D. was paid $1.7M in FY2025 (Dec), down 41%. Evolus stock fell 39.8% that year.

Pay$100 in the stock at the end of FY21 → $102
Pay is from the Summary Compensation Table of each Evolus proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. EvolusPublic company · 4 yr
    • Chief Medical Officer and Head of Research and Development2022 – Present · 4 yrStock in role +12%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?